Matthew D. Dallas
Nessuna posizione attualmente
Storia della carriera di Matthew D. Dallas
Precedenti posizioni note di Matthew D. Dallas
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ZEALAND PHARMA A/S | Direttore Finanziario/CFO | 07/10/2019 | 31/08/2022 |
| Contatto Relazioni con gli Investitori | 07/10/2019 | 31/08/2022 | |
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Direttore/Membro del Consiglio | 06/11/2018 | 03/02/2020 |
| Independent Dir/Board Member | 06/11/2018 | 03/02/2020 | |
| AVEO PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 01/06/2017 | 26/09/2019 |
| COLUCID PHARMACEUTICALS INC | Direttore Finanziario/CFO | 09/02/2015 | 01/03/2017 |
| Treasurer | 09/02/2015 | 01/03/2017 | |
| AVEO PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01/07/2014 | 06/02/2015 |
| Treasurer | 01/07/2014 | 06/02/2015 |
Formazione di Matthew D. Dallas
| University of Tennessee | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Danimarca | 2 |
Posizioni
| Director of Finance/CFO | 3 |
| Treasurer | 2 |
| Comptroller/Controller/Auditor | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| Aziende private | 2 |
|---|---|
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Matthew D. Dallas
- Esperienza
